Related Experiment Video
Updated: Apr 27, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.6K
Summary
Novartis is exchanging its vaccine division to GlaxoSmithKline (GSK) for a significant portion of GSK's oncology assets. This strategic asset swap aims to reshape both companies' portfolios in key therapeutic areas.
Area of Science:
- Pharmaceutical Industry
- Oncology
- Vaccinology
Background:
- Major pharmaceutical companies frequently engage in strategic asset exchanges to optimize their business portfolios.
- Novartis has a notable vaccine division, while GlaxoSmithKline possesses a strong cancer drug pipeline.
Purpose of the Study:
- To report on a significant asset swap between Novartis and GlaxoSmithKline (GSK).
- To outline the specific business units involved in the exchange: Novartis's vaccine business and GSK's cancer portfolio.
Main Methods:
- The primary method involves a direct asset exchange agreement between the two pharmaceutical giants.
- The transaction details the transfer of Novartis's vaccine business to GSK.
- The transaction details the transfer of a substantial part of GSK's oncology portfolio to Novartis.
Main Results:
- Novartis will transfer its vaccine business to GlaxoSmithKline.
- GlaxoSmithKline will transfer a significant portion of its cancer drug portfolio to Novartis.
- The agreement was finalized in late April, marking a major strategic shift for both companies.
Conclusions:
- This asset swap represents a significant strategic realignment for both Novartis and GlaxoSmithKline.
- The exchange allows each company to focus on and strengthen core areas of expertise: vaccines for GSK and oncology for Novartis.
More Related Videos
04:24Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
Published on: June 16, 2023
2.6K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.8K
Related Concept Videos
01:26Pharmaceutical Equivalents
272
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
272
01:30Production of Pharmaceuticals
90
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
90
01:26Drug Discovery: Overview
10.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.3K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
257
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226